BioCentury | Oct 3, 2020
Emerging Company Profile

OriCiro: replacing conventional bacterial cloning

...$3.6 million in series A funding from University of Tokyo Edge Capital...
...a method of amplifying circular DNA Danielle Golovin OriCiro Genomics Inc. University of Tokyo Edge Capital University...
BioCentury | Aug 14, 2020
Finance

Aug. 13 Quick Takes: Qiagen shareholders opt for independence; plus IPO terms from Inhibrx, Harmony and more from Biohaven-Royalty, Scioto, Bodyport, immunoSCAPE

...$11MSingapore-based ImmunoSCAPE raised $11 million in a financing led by Anzu Partners, with participation from University of Tokyo Edge Capital...
BioCentury | Apr 29, 2020
Emerging Company Profile

Bugworks: breaking the U.S.-centric antimicrobial mold

...in the U.S. and India in pneumonia patients, and could conclude as early as YE21. University of Tokyo Edge Capital...
...Colorado State University Corporate partners: None Number of employees: 23 Funds raised: $19 million Investors: University of Tokyo Edge Capital...
BioCentury | Jul 13, 2018
Financial News

Nohla adds $11M to series B

...close of a series B financing, bringing the round’s total to $56 million. New investors University of Tokyo Edge Capital...
BioCentury | Apr 14, 2014
Emerging Company Profile

Quantum: Silicon speed

...University Corporate partners: Not disclosed Number of employees: 15 Funds raised: $5.8 million Investors: JAFCO; University of Tokyo Edge Capital...
BioCentury | Jun 13, 2011
Finance

AIMing for Tokyo

...2002, Mebiopharm has raised ¥4.2 billion ($52.3 million). Investors include NIF SMBC Ventures; JAFCO; The University of Tokyo Edge Capital...
Items per page:
1 - 6 of 6
BioCentury | Oct 3, 2020
Emerging Company Profile

OriCiro: replacing conventional bacterial cloning

...$3.6 million in series A funding from University of Tokyo Edge Capital...
...a method of amplifying circular DNA Danielle Golovin OriCiro Genomics Inc. University of Tokyo Edge Capital University...
BioCentury | Aug 14, 2020
Finance

Aug. 13 Quick Takes: Qiagen shareholders opt for independence; plus IPO terms from Inhibrx, Harmony and more from Biohaven-Royalty, Scioto, Bodyport, immunoSCAPE

...$11MSingapore-based ImmunoSCAPE raised $11 million in a financing led by Anzu Partners, with participation from University of Tokyo Edge Capital...
BioCentury | Apr 29, 2020
Emerging Company Profile

Bugworks: breaking the U.S.-centric antimicrobial mold

...in the U.S. and India in pneumonia patients, and could conclude as early as YE21. University of Tokyo Edge Capital...
...Colorado State University Corporate partners: None Number of employees: 23 Funds raised: $19 million Investors: University of Tokyo Edge Capital...
BioCentury | Jul 13, 2018
Financial News

Nohla adds $11M to series B

...close of a series B financing, bringing the round’s total to $56 million. New investors University of Tokyo Edge Capital...
BioCentury | Apr 14, 2014
Emerging Company Profile

Quantum: Silicon speed

...University Corporate partners: Not disclosed Number of employees: 15 Funds raised: $5.8 million Investors: JAFCO; University of Tokyo Edge Capital...
BioCentury | Jun 13, 2011
Finance

AIMing for Tokyo

...2002, Mebiopharm has raised ¥4.2 billion ($52.3 million). Investors include NIF SMBC Ventures; JAFCO; The University of Tokyo Edge Capital...
Items per page:
1 - 6 of 6